AU2001277908A1 - Medicinal uses of mu-opioid receptor agonists - Google Patents
Medicinal uses of mu-opioid receptor agonistsInfo
- Publication number
- AU2001277908A1 AU2001277908A1 AU2001277908A AU7790801A AU2001277908A1 AU 2001277908 A1 AU2001277908 A1 AU 2001277908A1 AU 2001277908 A AU2001277908 A AU 2001277908A AU 7790801 A AU7790801 A AU 7790801A AU 2001277908 A1 AU2001277908 A1 AU 2001277908A1
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- mammal
- opioid receptor
- receptor agonists
- medicinal uses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000051367 mu Opioid Receptors Human genes 0.000 title abstract 2
- 108020001612 μ-opioid receptors Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 150000007650 D alpha amino acids Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002756 mu opiate receptor agonist Substances 0.000 abstract 1
- 229940126487 mu opioid receptor agonist Drugs 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 150000003667 tyrosine derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides methods for stimulating mu-opioid receptors with agonist peptides in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid residues has a positive charge. The amino acid residue in the first position is a tyrosine or tyrosine derivative. The amino acid in the second position is a D-α-amino acid. The present invention also provides methods of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the peptides.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21904600P | 2000-07-18 | 2000-07-18 | |
| US60219046 | 2000-07-18 | ||
| PCT/US2001/022563 WO2002005748A2 (en) | 2000-07-18 | 2001-07-18 | Medicinal uses of mu-opioid receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001277908A1 true AU2001277908A1 (en) | 2002-01-30 |
Family
ID=22817610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001277908A Abandoned AU2001277908A1 (en) | 2000-07-18 | 2001-07-18 | Medicinal uses of mu-opioid receptor agonists |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7498297B2 (en) |
| EP (1) | EP1303186B1 (en) |
| AT (1) | ATE496533T1 (en) |
| AU (1) | AU2001277908A1 (en) |
| CA (1) | CA2416475C (en) |
| DE (1) | DE60143945D1 (en) |
| WO (1) | WO2002005748A2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04007252A (en) | 2002-01-29 | 2005-03-31 | Wyeth Corp | Compositions and methods for modulating connexin hemichannels. |
| EP3842055A1 (en) * | 2003-02-04 | 2021-06-30 | Cornell Research Foundation, Inc. | Uses of aromatic-cationic peptide |
| CN100506841C (en) | 2003-05-01 | 2009-07-01 | 科内尔研究基金会 | Method and carrier complexes for delivering molecules to cells |
| WO2005015203A2 (en) * | 2003-08-06 | 2005-02-17 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor mu 1 (oprm1) |
| US7550439B2 (en) | 2004-01-23 | 2009-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| US20050282756A1 (en) * | 2004-06-18 | 2005-12-22 | Mehta Nozer M | Oral delivery of peptide pharmaceutical compositions |
| CN101027635A (en) * | 2004-09-22 | 2007-08-29 | 皇家飞利浦电子股份有限公司 | Data processing circuit wherein functional units share read ports |
| EP3549594A1 (en) | 2005-09-16 | 2019-10-09 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| EP3272353A1 (en) | 2008-02-07 | 2018-01-24 | Cornell University | Methods for preventing or treating insulin resistance |
| EP3741381B1 (en) | 2008-02-26 | 2024-04-24 | Cornell University | A peptide for use for prevention and treatment of acute renal injury |
| EP3906933A1 (en) * | 2009-03-20 | 2021-11-10 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
| EP2464371B1 (en) * | 2009-08-12 | 2016-03-16 | Cornell University | Methods for preventing or treating metabolic syndrome |
| EP4302829A3 (en) | 2009-08-24 | 2024-03-27 | Stealth BioTherapeutics Inc. | Peptide for use in preventing or treating macular degeneration |
| EP2764871A1 (en) * | 2009-10-05 | 2014-08-13 | Cornell University | Methods for the prevention or treatment of heart failure |
| US20160176930A1 (en) | 2010-07-09 | 2016-06-23 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
| US10293020B2 (en) | 2013-06-27 | 2019-05-21 | Stealth Biotherapeutics Corp. | Peptide therapeutics and methods for using same |
| WO2015183963A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| WO2016011318A1 (en) * | 2014-07-17 | 2016-01-21 | Cardimetrix Llc | Device for monitoring for effectiveness of heart failure therapy |
| EP3606938A1 (en) | 2017-04-05 | 2020-02-12 | Stealth BioTherapeutics Corp | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| CN116390723A (en) | 2020-09-09 | 2023-07-04 | 社会利益网络公司 | Methods and compositions for delivery of biotin to mitochondria |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350221B1 (en) * | 1988-06-30 | 1996-04-17 | Astra Aktiebolag | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same |
| US5602100A (en) * | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
| IS4261A (en) * | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | New peptide opioids for the treatment of pain and their use |
| SE9503924D0 (en) | 1995-08-18 | 1995-11-07 | Astra Ab | Novel opioid peptides |
| DE69630918T2 (en) * | 1995-06-09 | 2004-10-28 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Matrix for iontophoresis |
| SE9900961D0 (en) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
| US6900178B2 (en) * | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
-
2001
- 2001-07-18 US US10/333,485 patent/US7498297B2/en not_active Expired - Lifetime
- 2001-07-18 AU AU2001277908A patent/AU2001277908A1/en not_active Abandoned
- 2001-07-18 AT AT01955855T patent/ATE496533T1/en not_active IP Right Cessation
- 2001-07-18 CA CA2416475A patent/CA2416475C/en not_active Expired - Lifetime
- 2001-07-18 EP EP01955855A patent/EP1303186B1/en not_active Expired - Lifetime
- 2001-07-18 WO PCT/US2001/022563 patent/WO2002005748A2/en active Application Filing
- 2001-07-18 DE DE60143945T patent/DE60143945D1/en not_active Expired - Lifetime
-
2006
- 2006-06-29 US US11/427,606 patent/US7732398B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1303186B1 (en) | 2011-01-26 |
| US20070027070A1 (en) | 2007-02-01 |
| CA2416475C (en) | 2011-10-11 |
| EP1303186A4 (en) | 2007-02-07 |
| WO2002005748A2 (en) | 2002-01-24 |
| EP1303186A2 (en) | 2003-04-23 |
| DE60143945D1 (en) | 2011-03-10 |
| US7498297B2 (en) | 2009-03-03 |
| ATE496533T1 (en) | 2011-02-15 |
| US20040029796A1 (en) | 2004-02-12 |
| US7732398B2 (en) | 2010-06-08 |
| WO2002005748A3 (en) | 2002-03-28 |
| CA2416475A1 (en) | 2002-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001277908A1 (en) | Medicinal uses of mu-opioid receptor agonists | |
| WO2002048183A3 (en) | Compositions of peptide crystals | |
| BR9814499A (en) | Synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and process for treatment comprising administering an amount thereof | |
| NO20053761L (en) | Parenteral peptide formulations for the treatment of systemic lupus erythematosus. | |
| JP2002502396A (en) | LH-RH peptide analogs, their use and pharmaceutical compositions containing them | |
| JP2004521123A5 (en) | ||
| Coquerel et al. | Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin N | |
| CA2439598C (en) | Modified derivatives of cck-8 | |
| Griffiths et al. | Biotransformation of neuropeptides | |
| BADAMCHIAN et al. | Complete amino acid sequence analysis of a peptide isolated from the thymus that enhances release of growth hormone and prolactin | |
| AU668909B2 (en) | Phenylalanine analogs of bombesin | |
| HUT77979A (en) | Peptides, process for producing them and pharmaceutical compositions containing them | |
| Martinez et al. | Peptide hormones as prohormones | |
| US8361964B2 (en) | Growth hormone releasing factor (GRF) analogs and uses thereof | |
| EP0585444A4 (en) | Hepatoma treatment with somatostatin analogs | |
| Montero-Hadjadje et al. | Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands | |
| NL8302935A (en) | NEW POLYPEPTIDES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE POLYPEPTIDES AND THEIR USE. | |
| IE912629A1 (en) | Peptides | |
| WO1998021229A1 (en) | Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them | |
| MY140828A (en) | Therapeutic uses of tri-, tetra-, penta-, and polypeptides | |
| Audousset-Puech et al. | Synthesis of the C-terminal octapeptide of pig oxyntomodulin. Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala: a potent inhibitor of pentagastrin-induced acid secretion | |
| AU3433384A (en) | Pharmakologisch aktive peptide | |
| CA2257973A1 (en) | T cell antigen receptor peptides | |
| AU2005290844B2 (en) | Compounds that Modulate TRH Actions and Inhibit the TRH-Degrading Enzyme | |
| AU620184B2 (en) | Competitive gonadoliberin antagonists |